B-cell Lymphoma Clinical Trials in Beijing, Beijing Municipality

10 recruitingBeijing, Beijing Municipality, China

Showing 110 of 10 trials

Recruiting
Phase 2

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 2

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital100 enrolled1 locationNCT07461831
Recruiting
Early Phase 1

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

R/R Aggressive B-cell Lymphoma
Peking University People's Hospital18 enrolled1 locationNCT07344818
Recruiting
Phase 2

Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

B-cell Lymphoma Refractory
Daihong Liu10 enrolled1 locationNCT07321301
Recruiting
Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 1

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.200 enrolled3 locationsNCT04993690
Recruiting
Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253
Recruiting
Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80 enrolled30 locationsNCT06566586
Recruiting
Phase 1

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517
Recruiting
Phase 2

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478